A phase II study of zandelisib in patients with relapsed or refractory indolent non‐Hodgkin lymphoma: ME ‐401‐ K02 study
British Journal of Haematology · 2025
DOI: 10.1111/bjh.19994 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Wataru Munakata und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kyowa Kirin Co., Ltd..
Abstract (Originalsprache)
Zandelisib, a selective, potent PI3Kδ inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study. This phase II study evaluated the efficacy and safety of zandelisib for relapsed or refractory follicular lymphoma or marginal zone lymphoma. Sixty‐one patients received zandelisib orally at 60 mg daily continuously in the first two 28‐day cycles, followed by intermittent dosing on Days 1–7 following each cycle until progressive disease or unacceptable toxicity. Objective and complete response rates were 75.4% (95% confidence interval [CI], 62.7%–85.5%) and 24.6% (95% CI, 14.5%–37.3%) respectively. Median time to response was 58 days; 70.5% (43/61) of patients achieved their first response by Week 8. At least one Grade ≥ 3 treatment‐emergent adverse event (TEAE) occurred in 55.7% of patients: transaminase elevation (8.2%); cutaneous reactions (3.3%); and diarrhoea, enterocolitis and lung infection (1.6% each), defined as adverse events of special interest. The discontinuation rate due to any TEAE was 14.8%. No zandelisib‐related death occurred. Zandelisib showed favourable efficacy and tolerability in Japanese patients with relapsed or refractory indolent non‐Hodgkin B‐cell lymphoma. This unique dosing schedule may maintain efficacy while mitigating the safety issues observed with other PI3Kδ inhibitors (ClinicalTrials.gov number, NCT04533581).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
- Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan.
- Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan.
- Hematology, Tohoku University Hospital, Sendai, Japan.
- Oncology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
- Oncology and Hematology, Chiba Cancer Center, Chiba, Japan.
ORCID-Profile: Wataru Munakata, Yuko Mishima, Michiko Ichii, Koji Izutsu
Förderung
- Kyowa Kirin Co., Ltd.
Zitieren
APA
Munakata, W., Kumode, T., Goto, H., Fukuhara, N., Shimoyama, T., Takeuchi, M., Kawakita, T., Kubo, K., Sawa, M., Uchida, T., Mishima, Y., Ichii, M., Hanaya, M., Matsumoto, A., Kuriki, M., Seike, T., Izutsu, K., & Ishizawa, K. (2025). A phase II study of zandelisib in patients with relapsed or refractory indolent non‐Hodgkin lymphoma: ME ‐401‐ K02 study. British Journal of Haematology. https://doi.org/10.1111/bjh.19994
Vancouver
Munakata W, Kumode T, Goto H, Fukuhara N, Shimoyama T, Takeuchi M, et al. A phase II study of zandelisib in patients with relapsed or refractory indolent non‐Hodgkin lymphoma: ME ‐401‐ K02 study. British Journal of Haematology. 2025. doi:10.1111/bjh.19994
BibTeX
@article{Munakata2025,
author = {Munakata, Wataru and Kumode, Takahiro and Goto, Hideki and Fukuhara, Noriko and Shimoyama, Tatsu and Takeuchi, Masahiro and Kawakita, Toshiro and Kubo, Kohmei and Sawa, Masashi and Uchida, Toshiki and Mishima, Yuko and Ichii, Michiko and Hanaya, Miyoko and Matsumoto, Asuka and Kuriki, Masaaki and Seike, Toshihiro and Izutsu, Koji and Ishizawa, Kenichi},
title = {A phase II study of zandelisib in patients with relapsed or refractory indolent non‐Hodgkin lymphoma: ME ‐401‐ K02 study},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.19994}
}
EUVIMED